Login to Your Account

Clinic Roundup

Tuesday, September 18, 2012
• Jennerex Inc., of San Francisco, presented Phase II data on JX-594, its engineered oncolytic immunotherapy, delivered first intravenously and then through intra-tumoral route, demonstrating safety, disease control and tumor response in hepatocellular carcinoma (HCC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription